Zobrazeno 1 - 10
of 303
pro vyhledávání: '"Jonathan W. Goldman"'
Autor:
Mingchao Xie, Miljenka Vuko, Jaime Rodriguez-Canales, Johannes Zimmermann, Markus Schick, Cathy O’Brien, Luis Paz-Ares, Jonathan W. Goldman, Marina Chiara Garassino, Carl M. Gay, John V. Heymach, Haiyi Jiang, J. Carl Barrett, Ross A. Stewart, Zhongwu Lai, Lauren A. Byers, Charles M. Rudin, Yashaswi Shrestha
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-17 (2024)
Abstract Background We explored potential predictive biomarkers of immunotherapy response in patients with extensive-stage small-cell lung cancer (ES-SCLC) treated with durvalumab (D) + tremelimumab (T) + etoposide-platinum (EP), D + EP, or EP in the
Externí odkaz:
https://doaj.org/article/dac90161c2bf43f78841723ad0ac6b3b
Autor:
Jonathan W. Goldman, Lynette M. Sholl, Sanja Dacic, Michael C. Fishbein, Yonina R. Murciano-Goroff, Ravi Rajaram, Sylwia Szymczak, Anna M. Szpurka, Bo H. Chao, Alexander Drilon
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
The LIBRETTO-001 trial demonstrated the activity of the selective rearrangement during transfection (RET) inhibitor selpercatinib in advanced RET fusion-positive non-small cell lung cancer (NSCLC) and resulted in the drug’s approval for this indica
Externí odkaz:
https://doaj.org/article/ff2adc6f3eaf4f15b17c63e038b1aa62
Autor:
Clayton P. Smith, MD, Michael Xiang, MD, PhD, Stephanie M. Yoon, MD, Alan Lee, MD, Dan Ruan, PhD, Jonathan W. Goldman, MD, Amy L. Cummings, MD, Aaron Lisberg, MD, Edward B. Garon, MD, MS, Drew Moghanaki, MD, MPH
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 3, Pp 100468- (2023)
Introduction: Osimertinib is an effective treatment for metastatic NSCLC. Occasionally, thoracic radiation therapy (TRT) is delivered to patients receiving osimertinib to treat residual or progressing pulmonary tumors. Anecdotal reports suggest that
Externí odkaz:
https://doaj.org/article/b2b61572fb9f435fa78b46c90498509e
Autor:
David J. Benjamin, MD, Shuai Chen, PhD, Joanna B. Eldredge, MD, Shiruyeh Schokrpur, MD, Debory Li, Zhikuan Quan, MS, Jason W. Chan, MD, Amy L. Cummings, MD, Megan E. Daly, MD, Jonathan W. Goldman, MD, Matthew A. Gubens, MD, Jeremy P. Harris, MD, Mark W. Onaitis, MD, Viola W. Zhu, MD, PhD, Sandip P. Patel, MD, Karen Kelly, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 12, Pp 100427- (2022)
Introduction: There is a paucity of data on immune checkpoint inhibitors (ICIs) plus doublet chemotherapy (C) in patients with advanced lung cancer whose tumor harbors an actionable mutation. We sought to provide insight into the role of this combina
Externí odkaz:
https://doaj.org/article/3801fd9322224ff8af798db8607d43fe
Autor:
Yuanbin Chen, MD, PhD, Luis Paz-Ares, MD, PhD, Niels Reinmuth, MD, PhD, Marina Chiara Garassino, MD, Galina Statsenko, MD, Maximilian J. Hochmair, MD, Mustafa Özgüroğlu, MD, PhD, Francesco Verderame, MD, Libor Havel, MD, György Losonczy, MD, PhD, Nikolay V. Conev, MD, PhD, Katsuyuki Hotta, MD, PhD, MPH, Jun Ho Ji, MD, PhD, Stuart Spencer, MSc, Tapashi Dalvi, PhD, MPH, Haiyi Jiang, MD, Jonathan W. Goldman, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 6, Pp 100330- (2022)
Introduction: In the phase 3 study involving the use of durvalumab with or without tremelimumab in combination with platinum-based chemotherapy in untreated extensive-stage SCLC (CASPIAN study), first-line durvalumab plus platinum-etoposide (EP) sign
Externí odkaz:
https://doaj.org/article/1c079ba625de443f80bdb5548364cf07
Autor:
Jonathan W. Goldman, Minal Barve, Jyoti D. Patel, Antoinette Wozniak, Afshin Dowlati, Alexander Starodub, Taofeek K. Owonikoko, William Edenfield, Scott A. Laurie, Daniel Da Costa, Satwant Lally, Martina Koch, Matthew P. Kosloski, David Hoffman, Grace K. Dy
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 2, Pp 664-670 (2021)
Small cell lung cancer (SCLC) is a leading cause of cancer death worldwide, with few treatment options. Rovalpituzumab tesirine (Rova‐T) is an antibody‐drug conjugate that targets delta‐like 3 on SCLC cells to deliver a cytotoxic payload direct
Externí odkaz:
https://doaj.org/article/accac0c4d8ab4b6a908935af63ca37f0
Autor:
D. Ross Camidge, MD, PhD, Fabrice Barlesi, MD, PhD, Jonathan W. Goldman, MD, Daniel Morgensztern, MD, Rebecca Heist, MD, MPH, Everett Vokes, MD, Eric Angevin, MD, PhD, David S. Hong, MD, Igor I. Rybkin, MD, Minal Barve, MD, Todd M. Bauer, MD, Angelo Delmonte, MD, Martin Dunbar, DrPH, Monica Motwani, PhD, Apurvasena Parikh, PhD, Elysa Noon, PhD, Jun Wu, MD, Vincent Blot, PhD, Karen Kelly, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100262- (2022)
Introduction: Telisotuzumab vedotin (Teliso-V) is an anti-c-Met–directed antibody-drug conjugate that has exhibited antitumor activity as monotherapy in NSCLC. Its potential activity combined with programmed cell death protein-1 inhibitors has not
Externí odkaz:
https://doaj.org/article/5db379369d064b09bb9b7152b523f622
Autor:
Jonathan W. Goldman, Julien Mazieres, Fabrice Barlesi, Konstantin H. Dragnev, Marianna Koczywas, Tuncay Göskel, Alexis B. Cortot, Nicolas Girard, Claas Wesseler, Helge Bischoff, Ernest Nadal, Keunchil Park, Shun Lu, Alvaro Taus, Manuel Cobo, Shawn T. Estrem, Sameera R. Wijayawardana, Kellie Turner, Gerard Joseph Oakley, Karla C. Hurt, Alan Y. Chiang, Anwar M. Hossain, William J. John, Luis Paz-Ares
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
IntroductionJUNIPER compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, with erlotinib in patients with non-small cell lung cancer (NSCLC) harboring a Kirsten rat sarcoma (KRAS) mutation.MethodsJUNI
Externí odkaz:
https://doaj.org/article/4c938db73a4443b18e2317f0a0f304fd
Autor:
Jonathan W. Goldman, Basmah Abdalla, Melody A. Mendenhall, Anthony Sisk, Jaime Hunt, Gabriel M. Danovitch, Erik L. Lum
Publikováno v:
BMC Nephrology, Vol 19, Iss 1, Pp 1-4 (2018)
Abstract Background The management of malignancy post kidney transplantation includes reduction in immunosuppression and referral to an oncologist management of their malignancy. Recent advances in oncology have resulted in the approval of several cl
Externí odkaz:
https://doaj.org/article/0164bbccad8d43d6adb0e6296636931d
Autor:
Jonathan W. Goldman, David M. Waterhouse, Ben George, Peter J. O'Dwyer, Rafia Bhore, Sibabrata Banerjee, Larry Lyons, Chrystal U. Louis, Teng Jin Ong, Karen Kelly
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Introduction: Multicenter, phase I study of concurrent and delayed nivolumab plus nab-paclitaxel/carboplatin in advanced non-small cell lung cancer (NSCLC).Methods: Chemotherapy-naive patients with advanced NSCLC (ineligible for potentially curative
Externí odkaz:
https://doaj.org/article/36deb3212f774536b9f45353cdf8f360